The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1

Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139

Goodman & Gilman's The Pharmacological Basis of Therapeutics

Brunton, L. L. (1985) · Cited by 7,321

DrugBank: a comprehensive resource for in silico drug discovery and exploration

Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892

How to improve R&D productivity: the pharmaceutical industry's grand challenge

Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566

How many drug targets are there?

Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505

The druggable genome

Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305

Targeting cancer with small molecule kinase inhibitors

Zhang, J., Yang, P. L., & Gray, N. S. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2559 · Cited by 2,648

Protein kinases — the major drug targets of the twenty-first century?

Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,232

DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs

Knox, C., Law, V., Jewison, T., Liu, P., Ly, S., Frolkis, A., Pon, A., Banco, K., Mak, C., Neveu, V., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq1126 · Cited by 1,832

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798

Trends in GPCR drug discovery: new agents, targets and indications

Hauser, A. S., Attwood, M. M., Rask‐Andersen, M., Schiöth, H. B., & Gloriam, D. E. I. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.178 · Cited by 2,714

The evolution of commercial drug delivery technologies

Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361

G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?

Sriram, K., & Insel, P. A. (2018) · Molecular Pharmacology · doi:10.1124/mol.117.111062 · Cited by 1,258

Electrostatic Interactions in Protein Structure, Folding, Binding, and Condensation

Zhou, H., & Pang, X. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00305 · Cited by 1,214

Smart nanoparticles for cancer therapy

Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073

GPCRdb: an information system for G protein-coupled receptors

Ísberg, V., Mordalski, S., Munk, C., Rataj, K., Harpsøe, K., Hauser, A. S., Vroling, B., Bojarski, A. J., Vriend, G., & Gloriam, D. E. I. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1178 · Cited by 1,079

The druggable genome and support for target identification and validation in drug development

Finan, C., Gaulton, A., Krüger, F. A., Lumbers, R. T., Shah, T., Engmann, J., Galver, L., Kelley, R., Karlsson, A., Santos, R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1166 · Cited by 1,027

FDA-approved small-molecule kinase inhibitors

Wu, P., Nielsen, T. E., & Clausen, M. H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.005 · Cited by 1,040

The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands

Pawson, A. J., Sharman, J. L., Benson, H. E., Faccenda, E., Alexander, S. P. H., Buneman, O. P., Davenport, A. P., McGrath, J. C., Peters, J. A., Southan, C., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1143 · Cited by 845

SLC Transporters as Therapeutic Targets: Emerging Opportunities

Lin, L., Yee, S. W., Kim, R. B., & Giacomini, K. M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4626 · Cited by 835

Trends in kinase drug discovery: targets, indications and inhibitor design

Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 850

PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome

Kroeze, W. K., Sassano, M. F., Huang, X.-P., Lansu, K., McCorvy, J. D., Giguère, P. M., Sciaky, N., & Roth, B. L. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3014 · Cited by 755

Pharmacogenomics of GPCR Drug Targets

Hauser, A. S., Chavali, S., Masuho, I., Jahn, L. J., Martemyanov, K. A., Gloriam, D. E. I., & Babu, M. M. (2017) · Cell · doi:10.1016/j.cell.2017.11.033 · Cited by 637

Allosteric sodium in class A GPCR signaling

Katritch, V., Fenalti, G., Abola, E. E., Roth, B. L., Cherezov, V., & Stevens, R. C. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.03.002 · Cited by 525

International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G Protein–Coupled Receptors

Hamann, J., Aust, G., Araç, D., Engel, F. B., Formstone, C. J., Fredriksson, R., Hall, R. A., Harty, B. L., Kirchhoff, C., Knapp, B., et al. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009647 · Cited by 489

Emerging Diversity in Lipid–Protein Interactions

Corradi, V., Sejdiu, B. I., Galloso, H. M., Abdizadeh, H., Noskov, S. Y., Marrink, ‪. J., & Tieleman, D. P. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00451 · Cited by 470

Recent developments of HDAC inhibitors: Emerging indications and novel molecules

Bondarev, A. D., Attwood, M. M., Jonsson, J., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14889 · Cited by 451

The Concise Guide to PHARMACOLOGY 2013/14: Enzymes

Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12451 · Cited by 425

DGIdb 2.0: mining clinically relevant drug–gene interactions

Wagner, A. H., Coffman, A. C., Ainscough, B. J., Spies, N. C., Skidmore, Z. L., Campbell, K. M., Krysiak, K., Pan, D., McMichael, J. F., Eldred, J. M., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1165 · Cited by 413

Drug Affinity Responsive Target Stability (DARTS) for Small-Molecule Target Identification

Pai, M. Y., Lomenick, B., Hwang, H., Schiestl, R. H., McBride, W. H., Loo, J. A., & Huang, J. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-2269-7_22 · Cited by 365

How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets

Doak, B. C., Zheng, J., Dobritzsch, D., & Kihlberg, J. O. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01286 · Cited by 348

Drugging Membrane Protein Interactions

Yin, H. H., & Flynn, A. D. (2016) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-092115-025322 · Cited by 362

Cell permeability beyond the rule of 5

Matsson, P., Doak, B. C., Over, B., & Kihlberg, J. O. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.03.013 · Cited by 305

In silico design of novel probes for the atypical opioid receptor MRGPRX2

Lansu, K., Karpiak, J., Liu, J., Huang, X.-P., McCorvy, J. D., Kroeze, W. K., Che, T., Nagase, H., Carroll, F. I., Jin, J., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2334 · Cited by 293

Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales

Dahlén, A. D., Dashi, G., Maslov, I. O., Attwood, M. M., Jonsson, J., Trukhan, V., & Schiöth, H. B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.807548 · Cited by 308

Nanobodies to Study G Protein–Coupled Receptor Structure and Function

Manglik, A., Kobilka, B. K., & Steyaert, J. (2016) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104710 · Cited by 270

Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors

Vijayan, R., He, P., Modi, V., Duong‐Ly, K. C., Ma, H., Peterson, J. R., Dunbrack, R. L., & Levy, R. M. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501603h · Cited by 255

The Life of Pi Star: Exploring the Exciting and Forbidden Worlds of the Benzophenone Photophore

Dormán, G., Nakamura, H., Pulsipher, A., & Prestwich, G. D. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00342 · Cited by 249

Impact of Dynamically Exposed Polarity on Permeability and Solubility of Chameleonic Drugs Beyond the Rule of 5

Sebastiano, M. R., Doak, B. C., Backlund, M., Poongavanam, V., Over, B., Ermondi, G., Caron, G., Matsson, P., & Kihlberg, J. O. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00347 · Cited by 242

Drugging Undruggable Molecular Cancer Targets

Lazo, J. S., & Sharlow, E. R. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103440 · Cited by 234

ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors

Roskoski, R. J. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.06.001 · Cited by 226

GPCRdb: the G protein‐coupled receptor database – an introduction

Munk, C., Ísberg, V., Mordalski, S., Harpsøe, K., Rataj, K., Hauser, A. S., Kolb, P., Bojarski, A. J., Vriend, G., & Gloriam, D. E. I. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13509 · Cited by 224

Systematic functional profiling of transcription factor networks in Cryptococcus neoformans

Jung, K., Yang, D., Maeng, S., ‍Lee, K.-T., So, Y.-S., Hong, J., Choi, J., Byun, H.-J., Kim, H., Bang, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms7757 · Cited by 209

Advances in kinase targeting: current clinical use and clinical trials

Rask‐Andersen, M., Zhang, J., Fabbro, D., & Schiöth, H. B. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.09.007 · Cited by 186

Mechanisms of adhesion G protein–coupled receptor activation

Vizurraga, A., Adhikari, R., Yeung, J., Yu, M., & Tall, G. G. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.007423 · Cited by 179

Systematic functional analysis of kinases in the fungal pathogen Cryptococcus neoformans

‍Lee, K.-T., So, Y.-S., Yang, D., Jung, K.-W., Choi, J., Lee, D., Kwon, H., Jang, J., Wang, L. L., Cha, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12766 · Cited by 172

Design and Challenges of Radiopharmaceuticals

Vermeulen, K., Vandamme, M., Bormans, G. M., & Cleeren, F. (2019) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.07.001 · Cited by 152

An update on extra-oral bitter taste receptors

Tuzim, K., & Korolczuk, A. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03067-y · Cited by 148

Peptide-based protease inhibitors from plants

Hellinger, R., & Gruber, C. W. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.026 · Cited by 140

18F-Labeled Peptides: The Future Is Bright

Richter, S., & Wuest, F. R. (2014) · Molecules · doi:10.3390/molecules191220536 · Cited by 139

G-Protein-Coupled Receptors in CNS: A Potential Therapeutic Target for Intervention in Neurodegenerative Disorders and Associated Cognitive Deficits

Azam, S., Haque, M. E., Jakaria, M., Jo, S.-H., Kim, I., & Choi, D. (2020) · Cells · doi:10.3390/cells9020506 · Cited by 135

muTarget : A platform linking gene expression changes and mutation status in solid tumors

Nagy, Á. M., & Győrffy, B. (2020) · International Journal of Cancer · doi:10.1002/ijc.33283 · Cited by 124

Host-Directed Therapies for Tuberculosis: Figure 1.Preprint

Tobin, D. M. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021196 · Cited by 123

Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning

Wildenhain, J., Spitzer, M., Dolma, S., Jarvik, N., White, R., Roy, M. M., Griffiths, E., Bellows, D. S., Wright, G. D., & Tyers, M. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.003 · Cited by 125

Strategic Approaches to Improvise Peptide Drugs as Next Generation Therapeutics

Barman, P., Joshi, S., Sharma, S., Preet, S., Sharma, S., & Saini, A. (2023) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-023-10524-3 · Cited by 127

SZDB: A Database for Schizophrenia Genetic Research

Wu, Y., Yao, Y., & Luo, X. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw102 · Cited by 117

pathDIP: an annotated resource for known and predicted human gene-pathway associations and pathway enrichment analysis

Rahmati, S., Abovsky, M., Pastrello, C., & Jurišica, I. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1082 · Cited by 118

The Fragment Molecular Orbital Method Reveals New Insight into the Chemical Nature of GPCR–Ligand Interactions

Heifetz, A., Chudyk, E. I., Gleave, L., Aldeghi, M., Cherezov, V., Fedorov, D. G., Biggin, P. C., & Bodkin, M. J. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00644 · Cited by 116

Soluble ligands as drug targets

Attwood, M. M., Jonsson, J., Rask‐Andersen, M., & Schiöth, H. B. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0078-4 · Cited by 112

Gi/o-Protein Coupled Receptors in the Aging Brain

de Oliveira, P. G., Ramos, M. L., Amaro, A. J. M., Dias, R. A., & Vieira, S. I. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00089 · Cited by 111

Disciplined approach to drug discovery and early development

Plenge, R. M. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2608 · Cited by 102

The impact of in silico screening in the discovery of novel and safer drug candidates

Rognan, D. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.034 · Cited by 105

Opportunities and guidelines for discovery of orally absorbed drugs in beyond rule of 5 space

Poongavanam, V., Doak, B. C., & Kihlberg, J. O. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.05.010 · Cited by 97

HDX-MS guided drug discovery: small molecules and biopharmaceuticals

Marciano, D. P., Dharmarajan, V., & Griffin, P. R. (2014) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2014.08.007 · Cited by 98

The landscape of natural product diversity and their pharmacological relevance from a focus on the Dictionary of Natural Products®

Chassagne, F., Cabanac, G., Hubert, G., David, B., & Marti, G. (2019) · Phytochemistry Reviews · doi:10.1007/s11101-019-09606-2 · Cited by 104

Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research‐practice gaps, challenges, and insights

Zheng, P., Li, J., & Kros, J. M. (2017) · Medicinal Research Reviews · doi:10.1002/med.21463 · Cited by 101

Conformational Sampling of Macrocyclic Drugs in Different Environments: Can We Find the Relevant Conformations?

Poongavanam, V., Danelius, E., Peintner, S., Alcaraz, L., Caron, G., Cummings, M. D., Wlodek, S. T., Erdélyi, M., Hawkins, P. C. D., Ermondi, G., et al. (2018) · ACS Omega · doi:10.1021/acsomega.8b01379 · Cited by 91

Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic

Lencz, T., & Malhotra, A. K. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.28 · Cited by 87

Intracellular Transfer of Na+ in an Active-State G-Protein-Coupled Receptor

Vickery, O. N., Carvalheda, C. A., Zaidi, S. A., Pisliakov, A. V., Katritch, V., & Zachariae, U. (2017) · Structure · doi:10.1016/j.str.2017.11.013 · Cited by 88

Synaptic changes induced by melanocortin signalling

Caruso, V., Lagerström, M. C., Olszewski, P. K., Fredriksson, R., & Schiöth, H. B. (2014) · Nature reviews. Neuroscience · doi:10.1038/nrn3657 · Cited by 90

The Importance of Ligand-Receptor Conformational Pairs in Stabilization: Spotlight on the N/OFQ G Protein-Coupled Receptor

Miller, R. L., Thompson, A. A., Trapella, C., Guerrini, R., Malfacini, D., Patel, N., Han, G. W., Cherezov, V., Calò, G., Katritch, V., et al. (2015) · Structure · doi:10.1016/j.str.2015.07.024 · Cited by 81

Understanding Membrane Protein Drug Targets in Computational Perspective

Gong, J., Chen, Y., Pu, F., Sun, P., He, F., Zhang, L., Li, Y., Ma, Z., & Wang, H. (2018) · Current Drug Targets · doi:10.2174/1389450120666181204164721 · Cited by 82

Understanding transporter specificity and the discrete appearance of channel-like gating domains in transporters

Diallinas, G. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00207 · Cited by 79

In vitro expression and analysis of the 826 human G protein-coupled receptors

Lv, X., Liu, J., Shi, Q., Tan, Q., Wu, D., Skinner, J. J., Walker, A. L., Zhao, L., Gu, X.-X., Chen, N., et al. (2016) · Protein & Cell · doi:10.1007/s13238-016-0263-8 · Cited by 72

Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules

Bondarev, A. D., Attwood, M. M., Jonsson, J., Chubarev, V. N., Tarasov, V. V., Liu, W., & Schiöth, H. B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1057083 · Cited by 75

Computational design of thermostabilizing point mutations for G protein-coupled receptors

Popov, P. A., Peng, Y., Shen, L., Stevens, R. C., Cherezov, V., Liu, Z., & Katritch, V. (2018) · eLife · doi:10.7554/elife.34729 · Cited by 71

Trends in Drug Delivery Systems for Natural Bioactive Molecules to Treat Health Disorders: The Importance of Nano-Liposomes

Cardoso, R. V., Pereira, P. R., Freitas, C. S., & Paschoalin, V. M. F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122808 · Cited by 69

G Protein–Coupled Receptor (GPCR) Expression in Native Cells: “Novel” endoGPCRs as Physiologic Regulators and Therapeutic Targets

Insel, P. A., Wilderman, A. S., Zambon, A. C., Snead, A. N., Murray, F., Aroonsakool, N., McDonald, D., Zhou, S. M., McCann, T., Zhang, L., et al. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.098129 · Cited by 66

HTS-compatible FRET-based conformational sensors clarify membrane receptor activation

Scholler, P., Moreno‐Delgado, D., Lecat‐Guillet, N., Doumazane, E., Monnier, C., Charrier‐Savournin, F., Fabre, L., Chouvet, C., Soldevila, S., Lamarque, L., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2286 · Cited by 63

Orphan Drugs and Their Impact on Pharmaceutical Development

Attwood, M. M., Rask‐Andersen, M., & Schiöth, H. B. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.03.003 · Cited by 69

Discovery and Characterization of Novel GPR39 Agonists Allosterically Modulated by Zinc

Sato, S., Huang, X., Kroeze, W. K., & Roth, B. L. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.106112 · Cited by 61

Histone deacetylases and their inhibitors in inflammatory diseases

Zhang, S.-Y., Zhang, L., Wen, R., Yang, N., & Zhang, T. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117295 · Cited by 64

Integrating structural and mutagenesis data to elucidate GPCR ligand binding

Munk, C., Harpsøe, K., Hauser, A. S., Ísberg, V., & Gloriam, D. E. I. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.07.003 · Cited by 53

DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity

Schröder, M., Bullock, A. N., Fedorov, O., Bracher, F., Chaikuad, A., & Knapp, S. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00898 · Cited by 55

Recent advances in screening of enzymes inhibitors based on capillary electrophoresis

Cheng, M., & Chen, Z. (2018) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2018.05.002 · Cited by 53

Molecular assembly of rhodopsin with G protein-coupled receptor kinases

He, Y., Gao, X., Goswami, D., Hou, L., Pal, K., Yin, Y., Zhao, G., Ernst, O. P., Griffin, P. R., Melcher, K., et al. (2017) · Cell Research · doi:10.1038/cr.2017.72 · Cited by 52

Homogeneous Dual-Parametric-Coupled Assay for Simultaneous Nucleotide Exchange and KRAS/RAF-RBD Interaction Monitoring

Kopra, K., Vuorinen, E., Blanco, M. A., Wang, Q., Eskonen, V., Gillette, W., Pulliainen, A. T., Holderfield, M. T., & Härmä, H. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.9b05126 · Cited by 52

Advances in Capillary Electrophoresis-Based Enzyme Assays

Scriba, G. K. E., & Belal, F. F. (2015) · Chromatographia · doi:10.1007/s10337-015-2912-0 · Cited by 52

Integrating phosphoproteomics into kinase-targeted cancer therapies in precision medicine

Wu, X., Xing, X., Dowlut, D., Zeng, Y., Liu, J., & Liu, X. (2018) · Journal of Proteomics · doi:10.1016/j.jprot.2018.03.033 · Cited by 49

Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery

Hampel, H. J., Vergallo, A., Caraci, F., Cuello, A. C., Lemercier, P., Vellas, B. J., Giudici, K. V., Baldacci, F., Hänisch, B., Haberkamp, M., et al. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108081 · Cited by 52

CHARACTERISTICS OF DRUG COMBINATION THERAPY IN ONCOLOGY BY ANALYZING CLINICAL TRIAL DATA ON CLINICALTRIALS.GOV

Wu, M., Sirota, M., Butte, A., & Chen, B. (2014) · Pacific Symposium on Biocomputing · doi:10.1142/9789814644730_0008 · Cited by 55

Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer

Andradas, C., Blasco-Benito, S., Castillo‐Lluva, S., Dillenburg-Pilla, P., Dı́ez-Alarcia, R., Juanes-García, A., García-Taboada, E., Hernando-Llorente, R., Soriano, J., Hamann, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10206 · Cited by 51

Assays with Detection of Fluorescence Anisotropy: Challenges and Possibilities for Characterizing Ligand Binding to GPCRs

Rinken, A., Lavõgina, D., & Kopanchuk, S. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.10.004 · Cited by 49

Survey of Similarity-Based Prediction of Drug-Protein Interactions

Wang, C., & Kurgan, L. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190808154841 · Cited by 51

Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer’s Precision Medicine and Pharmacology

Hampel, H. J., Goetzl, E. J., Kapogiannis, D., Lista, S., & Vergallo, A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00310 · Cited by 47

Structure and Cooperativity in Substrate–Enzyme Interactions: Perspectives on Enzyme Engineering and Inhibitor Design

Rajakumara, E., Abhishek, S., Nitin, K., Saniya, D., Bajaj, P., Schwaneberg, U., & Davari, M. D. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.1c00500 · Cited by 49

Drug Discovery Opportunities at the Endothelin B Receptor-Related Orphan G Protein-Coupled Receptors, GPR37 and GPR37L1

Smith, N. J. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00275 · Cited by 47

PDID: database of molecular-level putative protein–drug interactions in the structural human proteome

Wang, C., Hu, G., Wang, K., Bryliński, M., Xie, L., & Kurgan, L. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv597 · Cited by 47

Bypass of Candida albicans Filamentation/Biofilm Regulators through Diminished Expression of Protein Kinase Cak1

Woolford, C. A., Lagree, K., Xu, W., Aleynikov, T., Adhikari, H., Sánchez, H., Cullen, P. J., Lanni, F., Andes, D. R., & Mitchell, A. P. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006487 · Cited by 46

Structural and Functional View of Polypharmacology

Moya‐García, A. A., Adeyelu, T. T., Krüger, F. A., Dawson, N. L., Lees, J., Overington, J. P., Orengo, C. A., & Ranea, J. A. G. (2017) · Scientific Reports · doi:10.1038/s41598-017-10012-x · Cited by 44

Systematic illumination of druggable genes in cancer genomes

Jiang, J., Yuan, J., Hu, Z., Zhang, Y., Zhang, T., Xu, M., Long, M., Fan, Y., Tanyi, J. L., Montone, K. T., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110400 · Cited by 47

Anti-cancer stemness and anti-invasive activity of bitter taste receptors, TAS2R8 and TAS2R10, in human neuroblastoma cells

Seo, Y., Kim, Y. S., Lee, K. E., Park, T. H., & Kim, Y. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176851 · Cited by 45

Recent Advances in Effect‐directed Enzyme Assays based on Thin‐layer Chromatography

Bräm, S., & Wolfram, E. (2017) · Phytochemical Analysis · doi:10.1002/pca.2669 · Cited by 47

Immobilized‐enzyme reactors integrated with capillary electrophoresis for pharmaceutical research

Schejbal, J., & Glatz, Z. (2017) · Journal of Separation Science · doi:10.1002/jssc.201700905 · Cited by 43

Clinical pharmacology applications in clinical drug development and clinical care: A focus on Saudi Arabia

Alsultan, A., Alghamdi, W. A., Alghamdi, J., Alharbi, A., Aljutayli, A., Albassam, A. A., Almazroo, O. A., & Alqahtani, S. (2020) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2020.08.012 · Cited by 41

Dynamic protein interfaces and conformational landscapes of membrane protein complexes

Kharche, S., & Sengupta, D. (2020) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2020.01.001 · Cited by 35

New Approaches to Difficult Drug Targets: The Phosphatase Story

Lazo, J. S., McQueeney, K. E., & Sharlow, E. R. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217721142 · Cited by 38

VB-MK-LMF: fusion of drugs, targets and interactions using variational Bayesian multiple kernel logistic matrix factorization

Bolgár, B., & Antal, P. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1845-z · Cited by 36

A drug target slim: using gene ontology and gene ontology annotations to navigate protein-ligand target space in ChEMBL

Mutowo, P., Bento, A. P., Dedman, N., Gaulton, A., Hersey, A., Lomax, J., & Overington, J. P. (2016) · Journal of Biomedical Semantics · doi:10.1186/s13326-016-0102-0 · Cited by 36

NMR analysis of GPCR conformational landscapes and dynamics

Casiraghi, M., Point, É., Pozza, A., Moncoq, K., Banères, J., & Catoire, L. J. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.12.019 · Cited by 37

Trends in the exploitation of novel drug targets

Rask-Andersen, M., Almén, M. S., & Schiöth, H. B. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3478 · Cited by 853

Trends in Exploration of Therapeutic Targets

Zheng, C. J., Han, L., Yap, C. W., Xie, B., & Chen, Y. (2005) · Drug News & Perspectives · doi:10.1358/dnp.2005.18.2.886480 · Cited by 14

The Therapeutic Target Database: an Internet resource for the primary targets of approved, clinical trial and experimental drugs

Liu, X., Zhu, F., Ma, X., Tao, L., Zhang, J., Yang, S., Wei, Y., & Chen, Y. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.586635 · Cited by 24

The evolving landscape of drug targets

Halip, L., Avram, S. I., Overington, J. P., Al‐Lazikani, B., Curpan, R. F., Sirimulla, S., Pushechnikov, A. O., Beccari, A. R., Savchuk, N., & Oprea, T. I. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01530-3

Construction of Enriched Resource for Primary Therapeutic Targets of Approved and Clinical Trial Drugs

Yang, H. J., Yu, C., Li, Y., & Zhu, F. (2017) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2017.53001